Mycenax Biotech Inc.

As of June 30, 2026, Mycenax Biotech Inc. carries a market capitalization of 5.30B, placing it among publicly traded companies globally. Its enterprise value stands at 6.16B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Mycenax Biotech Inc.'s next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, Mycenax Biotech Inc. has 207.04M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 6.50, and the price-to-book ratio stands at 3.76.

These figures are as of June 30, 2026. The EV/Sales ratio of 7.55 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 6.16B versus a market cap of 5.30B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Mycenax Biotech Inc. maintains a current ratio of 0.61, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 79.85, indicating elevated leverage, while an interest coverage ratio of -1.29 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Mycenax Biotech Inc. posted a negative return on equity (ROE) of -24.06, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -11.76, reflecting losses generated across the asset base. The company generates approximately 2.68M in revenue per employee across its workforce of 304.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 7.06 indicates how many times Mycenax Biotech Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Mycenax Biotech Inc. recorded an income tax benefit of -7.81M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -389.72M and -381.91M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Mycenax Biotech Inc.'s stock has declined approximately 35.49% over the past 52 weeks. The 50-day moving average sits at 23.54, while the 200-day moving average is 27.95.

Over the twelve months ended June 30, 2026, Mycenax Biotech Inc. generated 815.87M in revenue and converted that into -381.91M in net income, yielding earnings per share of -1.84. EBITDA reached -47.47M, while operating income came in at -354.55M.

As of June 30, 2026, Mycenax Biotech Inc. holds 264.94M in cash and equivalents against 1.12B in total debt, resulting in a net debt position of 718.21M. Total book value stands at 1.41B, with working capital of -561.95M providing operational flexibility.

Mycenax Biotech Inc. produced 122.68M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -146.46M in capital expenditures, free cash flow totaled -23.78M - equivalent to -0.11 per share.

Over the twelve months ended June 30, 2026, Mycenax Biotech Inc. posted a gross margin of -16.88, reflecting its pricing power and cost economics. The operating margin of -43.46 and net profit margin of -46.81 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.45: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1.23, meaning Mycenax Biotech Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Mycenax Biotech Inc.'s most recent stock split took place on December 17, 2012 with a 415:483 split ratio.

As of June 30, 2026, Mycenax Biotech Inc. has an Altman Z-Score of 1.06, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.